Gujarat Themis Biosyn Limited has informed the Exchange regarding Appointment of Mr. Nihar Parikh as Non- Executive Independent Director of the company w.e.f. August 01, 2025.
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Themis Biosyn announced multiple board decisions on August 1, 2025. Mr. Nihar Parikh, an entrepreneur and health-tech venture capitalist (formerly CEO of ZCL Chemicals/Zandu), has been appointed as Additional Non-Executive Independent Director, replacing Mr. Siddharth Kusumgar who will step down on September 20, 2025 after completing his second term. The company approved Q1 FY26 unaudited results showing total income of ₹36.15 crore (down from ₹39.35 crore YoY) and net profit of ₹9.06 crore (down ~31.5% from ₹13.24 crore YoY), with EPS at ₹0.83 vs ₹1.21. Importantly, the board decided NOT to proceed with the proposed merger with Themis Medicare Limited, choosing instead to focus on its core fermentation-based pharma intermediates and APIs business. A new multi-purpose API plant at Vapi commenced commercial production on May 1, 2025. The record date for the FY25 dividend was fixed as September 5, 2025.
Shareholders should note the weak Q1 performance with both revenue and profits declining year-on-year. The scrapping of the merger with Themis Medicare is a significant strategic shift, refocusing on core fermentation-based APIs supported by the newly operational Vapi plant. The incoming director brings relevant pharma and venture capital experience. A dividend remains on the table with the record date set.